Effect of atrial natriuretic peptide (8-33-Met ANP) in patients with hypertension

What Was Tested

This randomized controlled trial paper looks at ANP (Atrial Natriuretic Peptide).

In this pilot study the researchers investigated the effects of a 4-h infusion of atrial natriuretic peptide (8-33 Met ANP) on hemodynamic, renal, and hormonal parameters in 12 patients with hypertension.

Two hours after discontinuation of the infusion, systolic blood pressure was 126 +/- 6 and 135 +/- 7 mm Hg 4 h after the end of the infusion.

Who Took Part

According to the abstract, 12 patients were involved.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled, crossover and pilot.

Random assignment meant chance, not the researchers, decided who got ANP (Atrial Natriuretic Peptide) and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on ANP (Atrial Natriuretic Peptide), so expectations could not easily colour the readings.

Some patients received a placebo instead of ANP (Atrial Natriuretic Peptide), giving a reference point.

In the crossover set-up each of the patients took both ANP (Atrial Natriuretic Peptide) and the comparison in turn, acting as their own control.

What Was Measured

Topics PubMed links to this paper include Aldosterone, Atrial Natriuretic Factor, Blood Pressure, Bradycardia, Diuresis, Heart Rate and Hypertension.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of ANP (Atrial Natriuretic Peptide) in 12 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1992 (American journal of hypertension), a journal based in United States.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.